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introduction
The present guidelines cover the systemic subtypes of primary
nodal and primary extranodal peripheral T-cell lymphomas
(PTCLs). ESMO guidelines for primary cutaneous T-cell lymph-
omas are published separately [1]. Primary leukaemic PTCL sub-
types (i.e. T-cell prolymphocytic leukaemia, T-cell large granular
lymphocytic leukaemia, adult T-cell leukaemia/lymphoma and ag-
gressive NK-cell leukaemia) are not covered by the present guide-
lines. Primary nodal PTCLs include PTCL-not otherwise specified
(PTCL-NOS), anaplastic large-cell lymphoma (ALCL), both
fusion protein ALCL anaplastic lymphoma kinase positive (ALCL
ALK+) and ALCL anaplastic lymphoma kinase negative (ALCL
ALK−), and angioimmunoblastic T-cell lymphoma (AITL). The
primary extranodal PTCL subtypes covered by the present guide-
lines comprise enteropathy-associated T-cell lymphoma (EATL),
extranodal natural killer/T-cell lymphoma (ENKTCL), and hepa-
tosplenic T-cell lymphoma (HSTCL).
epidemiology
PTCLs are uncommon and heterogeneous malignant lymphopro-
liferative disorders that originate from post-thymic (peripheral)
T cells or mature natural killer (NK) cells. They represent 10%–
15% of all non-Hodgkin’s lymphomas. Nodal subtypes are the
most frequent in Caucasian patients (>80% of PTCL in Europe,
PTCL-NOS 34%, AITL 28%, ALCL ALK+ 6%, ALCL ALK− 9%)
[2]. In Asia, the PTCL incidence is higher due to the endemic oc-
currence of the Epstein-Barr virus (EBV)-associated ENKTCL
(44% of PTCL in Asia excluding Japan, where there is a relatively
higher frequency of adult T-cell leukaemia/lymphoma) [2]. EATL
is more frequent in Northern Europe (9%–10% as compared with
1%–2% in Asia) [2], where there is a higher occurrence of human
leukocyte antigen (HLA) haplotypes associated with coeliac
disease. Other PTCL subtypes have been associated with chronic
autoimmune disorders, such as HSTCL to Crohn’s disease [3]. In
PTCL, the male/female ratio is 2:1 and the median age at diagnosis
is between the sixth and seventh decades of life, but both sex and
age patterns vary according to different subtypes [2, 4, 5]. The
ALCL ALK+ subtype has a better prognosis than the other PTCL
entities, including its ALK−counterpart [6]. Recent reports have
suggested that the prognostic difference between ALCL ALK+ and
ALCL ALK− may at least be partly due to age-related differences
(ALK+ patients are generally younger than the other PTCL
patients) [7]. HSTCL occurs most frequently in younger to middle-
aged males in the setting of immunosuppressive treatment [8].
diagnosis
A PTCL diagnosis should be made by an expert haematopatholo-
gist and should, whenever possible, rely on an excisional tumour
tissue biopsy that provides enough material for formalin-fixed
samples. According to the WHO classification (2008), the distinc-
tion among different PTCL entities requires the integration of
the clinical picture, morphology, immunohistochemistry, flow
cytometry, cytogenetics, and molecular biology [3]. In PTCL, the
indication of the neoplastic nature of a given T-cell population is
based on (i) morphology, (ii) aberrant T-cell phenotype, and (iii)
clonally rearranged T-cell receptor (TCR) genes (αβ versus γδ
genotypes) [9].
Table 1 summarises the immunophenotype of the PTCL en-
tities covered by the present guidelines along with their TCR re-
arrangement features and putative cell of origin. Accumulating
evidence indicates that information on TCR and the cell of origin
plays an important role in both tumour biology and clinical be-
haviour, underscoring the clinical relevance of this information in
the light of an increasing number of targeted therapeutic options.
TIA1, granzyme B and perforin suggest a cytotoxic profile, which
may imply a more aggressive clinical behaviour in PTCL-NOS
[10]. At least three of the following markers: CD10, Bcl6,
CXCL13, PD1, SAP, ICOS, and CCR5 are suggestive of a follicular
T-helper (FTH) cell origin [9, 11, 12]. Although FTH cells are
considered to be the cell of origin in AITL, this diagnosis should
also be based on morphological parameters such as hyperplasia
of follicular dendritic cells (FDCs), arborising high endothelial†Approved by the ESMO Guidelines Committee: June 2015.
*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, via L. Taddei 4,
CH-6962 Viganello-Lugano, Switzerland.
E-mail: clinicalguidelines@esmo.org
cl
in
ic
al
pr
ac
tic
e
gu
id
el
in
es
clinical practice guidelines Annals of Oncology 26 (Supplement 5): v108–v115, 2015doi:10.1093/annonc/mdv201
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
 by guest on N
ovem
ber 15, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
venules and a substantial B-cell component, including EBV-
infected B-cell blasts [13]. ENKTCL cases show intra-cytoplasmic
CD3 (ɛ-chain), in contrast to other PTCL subtypes that only
express CD3 on the cell surface [3]. CD56 is helpful in differenti-
ating between EATL type I (CD8+/CD56−) and type II (CD8
−/CD56+), which is also more often γδ+ and is not associated
with coeliac disease [3]. CD30 plays a central role in the recogni-
tion of ALCL. ALCL is systematically PAX5-negative, frequently
epithelial membrane antigen (EMA)-positive and, in one-third of
the cases, CD45-negative. It is further categorised as ALK+ or
ALK− depending on the occurrence or lack of occurrence of the
classical t(2;5) translocation (or one of its variants) [3, 9]. CD20
and PAX5 allow for the identification of B-cell components and
can help in distinguishing ALCL ALK− from morphologically ag-
gressive classical Hodgkin’s lymphoma (PAX5+) with anaplastic
features. CD21 is useful in revealing the content of FDCs in AITL;
CD68 visualises the histiocytic component that can occasionally
outnumber the neoplastic cell population (e.g. lymphoepithelioid
PTCL-NOS, Lennert’s variant and the lymphohistiocytic variant
of ALCL). The assessment of EBV (Epstein-Barr encoding region
[EBER] in situ hybridisation) is important in T-cell malignancies,
as some of the entities (e.g. ENKTCL and a subset of PTCL-NOS)
show EBER positivity in the neoplastic cells.
staging and risk assessment
A complete blood count, routine blood chemistry including
lactate dehydrogenase (LDH), and uric acid as well as screening
tests for HIV, HTLV-1, and hepatitis B and C are required. At
baseline, patients should have at least a computed tomography
(CT) scan of the chest and abdomen, as well as a bone marrow
aspirate and biopsy. 18Fluorodeoxyglucose positron emission
tomography combined with computed tomography (18F-FDG
PET/CT) is increasingly used in nodal PTCL at baseline and re-
staging, but its role at the subtype-specific level still needs
further elucidation. PET may be useful for detecting residual
disease at the end of treatment, although residual FDG-avid
lesions lack specificity and biopsy confirmation is recommended.
The use of PET/CT is recommended in ENKTCL, where it is
documented to be a valuable modality for staging and treatment
planning [14–18].
prognostic indices
The International Prognostic Index (IPI) [19] is the most com-
monly used prognostic tool in nodal PTCL. A prognostic index
for PTCL-NOS [20] with later modification [21] has been pro-
posed, but does not univocally appear to be more useful than
the original IPI [4, 22]. For clinical practice purposes, the IPI is
therefore still the recommended tool. Male sex has been
reported as an adverse prognostic factor [5, 23]. In ENKTCL,
high EBV-DNA copy number is correlated with tumour load
and is an adverse outcome predictor [24].
treatment
nodal PTCL (PTCL-NOS, AITL, ALCL ALK+,
ALCL ALK−)
first-line treatment. Treatment strategies should be adapted
according to factors such as age, IPI, and co-morbidity that
Table 1. Nodal and extranodal PTCL subtypes—cell of origin and related phenotypes (adapted from [9])
PTCL entity Immunophenotypic features TCR Presumed cell of origin
Nodal PTCL-NOS CD4>CD8, frequent antigen loss (CD5, CD7), CD30+/−,
CD56+/−, subset FTH features, cytotoxic granules+/−
αβ, rarely γδ Variable, mostly T-helper cell
AITL CD4+, CD10+/−, BCL+/−, CXCL13+, PD1+, ICOS+/−,
SAP+/, CCR5+/−, hyperplasia of FDC, EBV+ B blasts
αβ FTH
ALCL ALK+ ALK+, CD30+, EMA+, CD25+, cytotoxic granules+, CD4+/−,
CD3+/−
αβ Cytotoxic T-cell
ALCL ALK- ALK−, CD30+, EMA+, CD25+, cytotoxic granules+, CD4+/−,
CD3+/−
αβ Cytotoxic T-cell
Extranodal EATL, type 1 CD8(+)/−, CD56−, HLA-DQ2/-DQ8 αβ Intra-epithelial T cells (αβ), pre-
existing enteropathy
EATL, type 2 CD8+, CD56+, HLA-DQ2/-DQ8 γδ or αβ Intra-epithelial T cells or NK,
no pre-existing enteropathy
NKTCL CD2+, CD56+, surface CD3−, cytoplasmic CD3ε+, gr B+,
TIA-1+, perforin+, EBV+, LMP1
TCR in germline
configuration, rarely
αβ or γδ
NK, rarely cytotoxic T cells
HSTCL CD3+, CD56+/−, CD4−, CD8+/−, CD5−, TIA1+, gr M+,
gr B−, perforin−
γδ, rarely αβ Cytotoxic T cell of the innate
immune system
PTCL, peripheral T-cell lymphomas; PTCL-NOS, PTCL-not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL ALK+, anaplastic
large-cell lymphoma anaplastic lymphoma kinase positive; ALCL ALK-, ALCL anaplastic lymphoma kinase negative; EATL, enteropathy-associated T-cell
lymphoma; NKTCL, natural killer/T-cell lymphoma; HSTCL, hepatosplenic T-cell lymphoma; FTH, follicular T helper; FDC, follicular dendritic cell;
EMA, epithelial membrane antigen; HLA, human leukocyte antigen; EBV, Epstein-Barr virus; TCR, T-cell receptor; NK, natural killer.
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define a patient’s eligibility for dose-intensified approaches.
Whenever possible, inclusion in a clinical trial is recommended.
A treatment algorithm for newly diagnosed PTCL is shown in
Figure 1A. Cyclophosphamide, hydroxydaunorubicin, vincristine
and prednisone (CHOP), or variants of it, has been the most
commonly used regimen in nodal PTCL. In patients less than 60
years of age with ALCL ALK+ histology, CHOP with the addition
of etoposide (CHOEP) has shown some outcome benefits in terms
of event-free but not overall survival (OS). CHOEP was mostly
feasible in younger patients (≤60 years), toxicity being a limiting
factor in older patients [25]. In a large cohort of treatment-naïve
PTCL patients, a schedule of 6 courses of bi-weekly CHOEP
followed by autologous stem-cell transplantation (autoSCT)
demonstrated an overall response rate (ORR) of 82%, with 51%
achieving a complete response (CR) [23]. At a median follow-up
of 4.5 years, the three included nodal PTCL entities had an
estimated 5-year OS and a progression-free survival (PFS) of
70% and 61% (ALCL ALK−), 52% and 49% (AITL) and 47%
and 38% (PTCL-NOS). Recent population-based data also
indicate that upfront autoSCT in chemosensitive patients is
associated with improved OS [5]. On the basis of these data, a
dose-dense CHOEP schedule followed by autoSCT in
chemosensitive and transplant-eligible patients represents an
evidence-based approach adoptable outside of a clinical trial [III,
B] (Figure 1A).
Other induction regimens have been tried, e.g. platinum and
gemcitabine combinations. In newly diagnosed patients, a recent
phase II trial testing the PEGS regimen (cisplatin, etoposide, gem-
citabine, and methylprednisolone) revealed a disappointing ORR
of 39% and a 2-year PFS of only 14% [26]. Therefore, although
the role of anthracyclines in PTCL is still debated, anthracycline-
void regimens have, so far, failed to demonstrate their superiority
to CHOP/CHOEP as the standard chemotherapy regimen
outside clinical trials. In low-risk (low-/low-intermediate IPI)
ALCL ALK+ patients, consolidation with autoSCT is not recom-
mended, since these patients seem to have a more favourable
outcome compared with other PTCL subtypes, with a 5-year
failure-free survival (FFS) of 60%–80% [6]. The few patients with
truly localised (stage I) disease should receive a shortened chemo-
therapy schedule (e.g. 3 courses), followed by local radiotherapy,
since retrospective analyses seem to indicate a survival advantage
for a combined modality approach in early stage disease [27–29]
(see ‘Radiotherapy’ section). Frail patients not eligible for inten-
sive chemotherapy schedules may be considered for less toxic
approaches such as monotherapy schedules, e.g. with gemcitabine
[30] or bendamustine [31].
relapse. Although a fair number of patients with nodal PTCL are
chemosensitive, their response duration is often short and relapses
are frequent. Except for CD30+ ALCL, there is no standard of care
for relapsed/refractory nodal PTCL. The only globally approved
salvage treatment in PTCL is the anti-CD30 antibody conjugate
brentuximab vedotin (BV) administered in the setting of relapsed
systemic ALCL (regardless of the ALK status). In a pivotal phase II
study, BV monotherapy in heavily pre-treated, noncutaneous
ALCL patients yielded an ORR of 86% and a CR rate of 57%,
with a median response duration of 12.6 months [32]. Anti-
CD30-directed BV monotherapy in relapsed/refractory ALCL is,
therefore, evidence-supported and recommended [III, A]. This
treatment may also be useful to bridge eligible patients towards
allogeneic stem-cell transplantation (alloSCT). A proposed
treatment algorithm is summarised in Figure 1B. For relapsed/
refractory nodal PTCL other than ALCL, inclusion into clinical
trials is highly encouraged. Outside clinical trials, in fit patients,
combination chemotherapy regimens such as DHAP
(dexamethasone, high-dose cytarabine, cisplatin) or ICE (ifosphamide,
etoposide, carboplatin) can be attempted in chemosensitive
patients with an available donor, aiming at alloSCT as a
potentially curative modality. In unfit patients, monotherapy with
gemcitabine or bendamustine are generally well-tolerated, with
an ORR of approximately 50% but with modest durations of
response [30, 31]. Promising new drugs are under current
evaluation in clinical trials. Of these new compounds, the anti-
folate pralatrexate and the histone deacetylase inhibitors
romidepsin and belinostat, have recently been conditionally
approved in the US, based on phase II trial results [33, 34]. The
same is the case for the anti-CCR4 antibody mogamulizumab,
whose label in Japan has recently been extended from adult T-cell
leukaemia/lymphoma to cover also relapsed/refractory PTCL and
transformed mycosis fungoides [35]. Phase III studies are
ongoing in the upfront setting for all of these new compounds.
EATL
first-line treatment. In EATL, outcome after standard CHOP
chemotherapy is generally poor. Recent reports indicate that, for
patients sufficiently fit to tolerate more aggressive chemotherapy
regimens, outcome can be significantly improved. A regimen
with ifosphamide, vincristine, etoposide, and methotrexate (IVE/
MTX) followed by autoSCT has shown promising results, with
5-year OS and PFS of 60% and 52%, respectively [36]. In
addition, CHOEP-14 consolidated with autoSCT has shown
improved outcomes compared with standard CHOP [III, B] [23].
In a European Society for Blood and Marrow Transplantation-
based registry study, 4-year OS and PFS for EATL patients
receiving intensive induction regimens followed by autoSCT in first
CR/partial response (PR) were 59% and 54%, respectively [37]. It is
difficult to estimate the proportion of all EATL patients amenable
to intensive therapies, but at least one-half of the patients aged <70
years may be considered for standard-dose chemotherapy. If these
patients respond to therapy, their performance status may improve,
thus allowing for subsequent autoSCT.
relapse. No evidence-based specific relapse regimen can be
recommended in relapsed/refractory EATL. Therefore,
considerations similar to those described for ‘nodal entities’ (see
above) are also applicable to relapsed/refractory EATL. In
transplant-eligible patients who retain chemosensitivity at relapse
and have a suitable donor, alloSCT should be attempted.
ENKTCL
first-line treatment. The treatment strategy for this subtype of
lymphoma is unique in the context of PTCL. L-asparaginase-
containing regimens such as SMILE (dexamethasone, methotrexate,
ifosphamide, L-asparaginase, etoposide) and AspaMetDex
(L-asparaginase, methotrexate, dexamethasone) have produced
promising results [38, 39]. Anthracycline-based regimens (CHOP
or CHOP-like) are not effective [40]. Addition of radiation to
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A B
Figure 1. Integrated management algorithm (according to, e.g. risk factors, stage and histological subtype) in the (A) front-line and (B) relapsed/refractory setting. (A) § Stage I: shortened chemotherapy schedule
(e.g. 3 courses) followed by curatively intended RT (see ‘Radiotherapy’ section). *ALCL ALK+ with a high-risk profile (e.g. IPI >2) should be considered for autoSCT consolidation, while autoSCT in low risk profile
patients is not recommended. # if donor available. ¤ SMILE or AspaMetDex. (B) $: Pralatrexate and romidepsin: FDA but not EMA approved. PTCL, peripheral T-cell lymphomas; PTCL-NOS, PTCL-not otherwise
specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL ALK+, anaplastic large-cell lymphoma anaplastic lymphoma kinase positive; ALCL ALK-, ALCL anaplastic lymphoma kinase negative;
EATL, enteropathy-associated T-cell lymphoma; HSTCL, hepatosplenic T-cell lymphoma; ENKTCL, extranodal natural killer/T-cell lymphoma; CHOEP, cyclophosphamide, hydroxydaunorubicin, vincristine,
etoposide, prednisone; CHOP, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone; IVE/MTX, ifosfamide, vincristine, etoposide/methotrexate; ICE, ifosphamide, etoposide, and carboplatin; IVAC,
ifosphamide, cytarabine, etoposide; PR, partial response; CR, complete response; alloSCT, allogeneic stem-cell transplantation; autoSCT, autologous stem-cell transplantation; rel/ref, relapsed/refractory;
BV, brentuximab vedotin; DHAP, dexamethasone, high-dose cytarabine, cisplatin; SMILE, dexamethasone, methotrexate, ifosphamide, L-asparaginase, etoposide; CS, clinical stage; RT, radiotherapy.
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chemotherapy is the preferred treatment of localised disease [40].
EBV DNA copy number from plasma or whole blood can be
used as a biomarker for response; therefore, serial monitoring of
EBV DNA copy number is recommended [15]. ENKTCL is
FDG-avid, and although the role of PET/CT for response
evaluation is not yet fully clarified, PET/CT is the recommended
imaging modality in ENKTCL.
stages I–II. Most patients present with stage I–II nasal disease.
In these cases, radiation combined with chemotherapy is the
preferred treatment [40, 41]. Concurrent chemoradiotherapy
and sequential chemotherapy with L-asparaginase-containing
regimens followed by radiation appear to have comparable efficacy
[III, A]. A radiation dose >50 Gy is recommended when treating
with radiation alone. However, with radiosensitisers such as
cisplatin, a weekly dose of ∼40 Gy can give a comparable outcome.
Central nervous system prophylaxis is not recommended, although
the disease involves nasal and/or paranasal areas. Instances of
localised disease outside the nasal region are rare. If feasible,
radiation with or without chemotherapy seems to be a more
effective treatment compared with chemotherapy alone. The role of
high-dose chemotherapy followed by haematopoietic stem-cell
transplantation (HSCT) is still controversial. For elderly and/or frail
patients, radiation alone is recommended.
stages III–IV. L-asparaginase-containing chemotherapy regi-
mens should be preferred as front-line treatment [III, A]. If complete
remission is achieved, high-dose chemotherapy with HSCT is recom-
mended. AutoSCT is preferable due to higher treatment-related mor-
tality after alloSCT. For elderly and frail patients, L-asparaginase
single agent or mild chemotherapy regimens (AspaMetDex or dose-
modified SMILE) can be recommended [42].
relapse. A repeated pre-therapeutic biopsy is strongly recom-
mended, since some of the PET-positive lesions can represent
inflammatory changes secondary to ulceration. Selection of a
salvage regimen depends on the type of primary treatment and
response duration. In early relapse (<12 months) after anthracy-
cline-based prior treatment, L-asparaginase-containing regimens
should be recommended. For patients who received L-asparagi-
nase regimens upfront, a gemcitabine-based (e.g. GELOX, gem-
citabine, L-asparaginase, oxaliplatin) regimen can be considered
for salvage treatment [41]. Although transplant-specific data are
very limited, either auto- or alloSCT should be considered in
transplant-eligible patients. Both modalities should preferably
be tested in clinical trials.
HSTCL
first-line treatment. HSTCL has one of the worst prognoses
among PTCLs, with 5-year FFS and OS rates of less than 10%. All
cases should be treated with chemotherapy at diagnosis. Although
most patients have only brief responses to anthracycline-based
therapy, limited evidence suggests that they may respond to a
platinum/cytarabine-based induction regimen. In the case of
chemosensitivity to induction therapy, upfront consolidation with
auto- or alloSCT should be offered to all eligible patients, since it
may offer the only chance for durable remission [8, 43]. Recently,
intense regimens such as ICE, IVAC (ifosphamide, cytarabine,
etoposide), or dose-dense CHOEP/EPOCH (etoposide, vincristine,
doxorubicin, cyclophosphamide and prednisone) have been
proposed and auto- or alloSCT consolidation in fit patients is
recommended [IV, B] [23, 44].
relapse. No evidence-based specific relapse regimen can be
recommended in relapsed/refractory HSTCL. If chemosensitivity
is achieved by current relapse regimens, alloSCT should be
attempted in eligible patients, since a graft-versus-host effect has
also been described in relapsed/refractory disease.
radiotherapy
PTCL seem to be somewhat less radiosensitive than the aggres-
sive B-cell lymphomas [45], and higher radiation doses may be
needed, although still lower than for most solid tumours.
front-line treatment
Most types of PTCLs usually present with advanced disease.
The few patients with localised disease may be treated with local
radiotherapy after chemotherapy [27–29], although no rando-
mised evidence regarding this approach exists. Recommended
doses are 30–40 Gy [46]. Because of the somewhat lower radio-
sensitivity of PTCLs, doses of 40 Gy should be preferred, in par-
ticular if residual lymphoma is present after chemotherapy. The
treated volume should include only the initially involved volume
with appropriate margins for uncertainty, according to the prin-
ciples of involved site radiotherapy (ISRT) [47]. High-quality
imaging before chemotherapy should be obtained in order to
allow for optimal planning of subsequent radiotherapy. Modern
advanced radiation treatment techniques should be used to min-
imise long-term toxicity [47].
ENKTCLs have special features. They most commonly
involve the nasal cavity, paranasal sinuses, and Waldeyer’s ring.
Radiotherapy is an important part of the treatment and should
be administered early [III, A] [15, 48]. Patients with stage I
disease may be treated with radiotherapy alone to a dose of
≥50 Gy [49]. Alternatively, and for patients with risk factors or
stage II disease, concomitant chemoradiotherapy with a plat-
inum-containing regimen and radiotherapy dose of ≥50 Gy is
an option [41]. With more effective chemotherapy regimens, se-
quential chemoradiation with radiation doses of 45–50 Gy may
be used. ENKTCL is often locally destructive and may infiltrate
extensively in the submucosa of the upper aerodigestive tract.
A generous ISRT volume is recommended, covering the entire
organ(s) involved with lymphoma before chemotherapy plus ad-
jacent structures with concern for subclinical disease. Advanced
imaging including PET/CT and magnetic resonance imaging and
conformal radiotherapy techniques should be used.
relapse/refractory disease
Palliative radiotherapy may be used to treat locally symptomatic
disease. Usual palliative doses of 30 Gy in 10 fractions may
be used.
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autologous stem-cell transplantation
(autoSCT)
front-line treatment
There are no randomised prospective studies to guide clinicians
in the decision on whether to perform autoSCT consolidation in
first remission versus expectant observation. A body of pro-
spective literature has accumulated that evaluates an up-front
autoSCT in PTCL [23, 50–52]. Recent population-based data
also indicate that upfront autoSCT in chemosensitive patients is
associated with improved OS [5]. The nodal entities (PTCL-
NOS, AITL, and ALCL mostly restricted to ALK− cases) re-
present the majority of patients enrolled in clinical trials. ALCL
ALK+ patients usually have been excluded from upfront
autoSCT trials, given their superior outcome following CHOP
or CHOP-like regimens. The largest prospective study evaluat-
ing autoSCT consolidation in de novo PTCL was carried out by
the Nordic group, where patients achieving CR or PR after a
CHOEP-based dose-dense induction schedule received BEAM
(carmustine, etoposide, cytarabine, melphalan) conditioning
and autoSCT. With the caveat of phase II data, autoSCT in first
remission seems quite feasible and possibly beneficial in the
selected subset of transplant-eligible PTCL [III, B].
allogeneic stem-cell transplantation
(alloSCT)
AlloSCT is a potentially curative option for patients affected by
PTCL. The first prospective phase II results demonstrated sus-
tained responses in relapsed/refractory PTCL patients, suggest-
ing the existence of a possible ‘graft-versus-T-cell lymphoma’
effect [III, B] [53, 54]. Non-relapse mortality (NRM) was low,
supporting the feasibility of a reduced-intensity conditioning
alloSCT (RIC-alloSCT) even in heavily pre-treated patients.
Retrospective and registry-based analyses also confirmed that
alloSCT can yield long-term responses in relapsed/refractory
PTCL [55–58]. In extranodal subtypes data are anecdotal, but
generally supportive of the feasibility and efficacy of alloSCT. In
a recently reported prospective trial carried out in treatment-
naïve PTCL patients, after an induction phase with intensive
chemoimmunotherapy, responding patients were randomised to
auto- or alloSCT based on the availability of a HLA identical
sibling or a matched unrelated donor [59]. The sample size did
not allow identification of a preferred approach among the two;
however, allo- and autografted patients had a 4-year PFS of 69%
and 70%, respectively. In conclusion, alloSCT is a valid treatment
option in transplant-eligible relapsed PTCL patients, also after a
failed prior autograft. The benefit is most evident in chemosensi-
tive patients. A RIC-alloSCT should be preferred to a myeloabla-
tive approach in order to reduce NRM. In the upfront setting,
alloSCT should be carried out primarily within clinical trials.
relapsed/refractory disease
For patients with relapsed/refractory PTCLs, potential curative
options include consolidation with either an autoSCT or alloSCT.
Although often appropriately offered, not all patients are able to
have a transplant due to highly refractory and progressive disease.
The literature remains controversial with regard to the long-term
outcomes with autoSCT in this setting [60].
personalised medicine
Two personalised approaches are currently widely accepted
and formally approved in the treatment of PTCL. One is the use
of L-asparaginase in the treatment of ENKTCL and the other
is the use of the anti-CD30 antibody conjugate BV for the treat-
ment of relapsed/refractory ALCL also with the purpose of
bridging eligible patients to alloSCT. BV is also currently being
tested as part of the upfront treatment in CD30-positive PTCL
other than ALCL. Increasing knowledge of the molecular
mechanisms involved in PTCL pathogenesis is accumulating.
This may lead to new and more targeted treatment approaches
in the near future. Currently, no evidence-based personalised
medicine approaches are available for patients with PTCL-NOS,
AITL, EATL, and HSTCL. In these settings, more research is
needed to identify molecular markers which could lead to
advances in personalised medicine.
response evaluation and follow-up
In systemic PTCL, a midway interim evaluation should be
carried out in order to assess chemosensitivity. Increasing evi-
dence points at PTCL as consistently FDG-avid tumours [61, 62]
providing the rationale for the use of PET/CT, particularly in the
context of residual disease evaluation. Diagnostic imaging (CT or
PET/CT) should be repeated at the end of treatment along with a
bone marrow biopsy (only if initially involved). Presently, no evi-
dence-based recommendation is possible with regard to the
length of follow-up. However, in the Nordic NLG-T-01 trial,
where a cohort of 160 evaluable systemic PTCL patients were fol-
lowed over a median period of 5 years (range: 2–8 years), 7% of
all relapses occurred after 2 years [23]. On this basis, a follow-up
schedule consisting of history and physical examination every 3
months for 1 year, every 6 months for 2 more years, and then
once a year for detection of secondary tumours or other long-
term side-effects [V, C]. CT examinations at 6, 12, and 24
months after the end of treatment are usual practice, but there is
no definitive evidence that routine imaging in patients in com-
plete remission provides any outcome advantage [V, C]. Routine
surveillance with PET scan is not recommended.
methodology
These clinical practice guidelines were developed in accordance
with the ESMO standard operating procedures for clinical prac-
tice guidelines development. The relevant literature has been
selected by the expert authors. Levels of evidence and grades of
recommendation have been applied using the system shown in
Table 2. Statements without grading were considered justified
standard clinical practice by the experts and the ESMO faculty.
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